Therapeutic potential of GLP1RAs in diabetic sensorimotor polyneuropathy

Gordon Sloan, Dinesh Selvarajah, Dan Ziegler, Solomon Tesfaye
Nature Reviews Endocrinology · Springer Nature · 2026-11-19 · DOI: 10.1038/s41574-026-01338-6

Аннотация

Nature Reviews Endocrinology, Published online: 19 November 2026; doi:10.1038/s41574-026-01338-6 The introduction of glucagon-like peptide 1 receptor agonists (GLP1RAs) has transformed the care of patients with type 2 diabetes mellitus. Increasingly, evidence indicates that the benefits of GLP1RAs extend beyond lowering glucose levels; however, limited research has focused on diabetic sensorimotor polyneuropathy.

Читать у издателя →

Похожие статьи